Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T22:52:46.196Z.
Calculation as of: 2026-10-06T22:52:46.196Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: c51f7bb38e0467dbdaec2b87e904118633479c78190bb705d814f7e841715b6d
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
SELLAS Life Sciences Group, Inc.
Market Cap
$2.11B
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$2.11B
Price/OCF Ratio
13.01
TTM Avg
16.43
3Y Avg
16.61
5Y Avg
17.87
Market Cap
$2.13B
Price/OCF Ratio
N/A
TTM Avg
151.58
3Y Avg
151.58
5Y Avg
151.58
Market Cap
$2.06B
Price/OCF Ratio
N/A
TTM Avg
8.03
3Y Avg
6.03
5Y Avg
5.71
Market Cap
$2.17B
Price/OCF Ratio
N/A
TTM Avg
35.55
3Y Avg
17.39
5Y Avg
17.83
| NAME | MARKET CAP | PRICE/OCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | $2.11B | N/A | N/A | N/A | N/A |
| Vera Therapeutics, Inc. (VERA)vs › | $2.11B | N/A | N/A | N/A | N/A |
| Addus HomeCare Corporation (ADUS)vs › | $2.11B | 13.01 | 16.43 | 16.61 | 17.87 |
| GeneDx Holdings Corp. (WGS)vs › | $2.13B | N/A | 151.58 | 151.58 | 151.58 |
| Alvotech (ALVO)vs › | $2.08B | N/A | N/A | N/A | N/A |
| Viridian Therapeutics, Inc. (VRDN)vs › | $2.06B | N/A | N/A | N/A | N/A |
| Celldex Therapeutics, Inc. (CLDX)vs › | $2.06B | N/A | 8.03 | 6.03 | 5.71 |
| Maravai LifeSciences Holdings, Inc. (MRVI)vs › | $2.17B | N/A | 35.55 | 17.39 | 17.83 |
| Vericel Corporation (VCEL)vs › | $2.05B | 29.44 | 33.23 | 46.35 | 53.29 |
| Pharvaris N.V. (PHVS)vs › | $2.17B | N/A | N/A | N/A | N/A |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
